Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement

Summary by Laotian Times
MELBOURNE, Australia and INDIANAPOLIS, April 7, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a market update on its commercial and operational performance for the quarter ended March 31, 2026 (Q1 2026). Q1 2026 Highlights Q1 2026 unaudited Group revenue of US$230 million, up 11% quarter-over-quarter. FY 2026 revenue guidance of US$950 […]
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

4 Articles

TelixTelix
+3 Reposted by 3 other sources

Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement

Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement Melbourne (Australia) and Indianapolis (United States) | April 7, 2026 Telix provides a market update on its commercial and operational performance for the quarter ended March 31, 2026 (Q1 2026). Q1 2026 Highlights Q1 2026 unaudited Group revenue of US$230 million, up 11% quarter-over-quarter. FY 2026 revenue guidance of US$950 million to US$970 million is reaffirmed. Pre…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Telix broke the news on Monday, April 6, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Melbourne, Australia icon

Melbourne, Australia

Indianapolis icon

Indianapolis

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal